MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

Prexasertib dimesylate

CAS No. : 1234015-58-7

MCE 站：Prexasertib dimesylate

产品活性：Prexasertib dimesylate (LY2606368 dimesylate) 是一种选择性的，ATP 竞争性的第二代细胞周期检测点激酶 1 (CHK1) 抑制剂，K_i 为 0.9 nM，IC₅₀ 为 <1 nM。Prexasertib dimesylate 抑制 CHK2 (IC₅₀=8 nM) 和 RSK1 (IC₅₀=9 nM)。Prexasertib dimesylate 引起双链 DNA 断裂和复制突变，导致细胞凋亡 (apoptosis)。Prexasertib dimesylate 显示有效的抗肿瘤活性。

研究领域：Cell Cycle/DNA Damage  |  Apoptosis

作用靶点：Checkpoint Kinase (Chk)  |  Apoptosis

In Vitro: Prexasertib dimesylate (LY2606368 dimesylate) inhibits MELK (IC₅₀=38 nM), SIK (IC₅₀=42 nM), BRSK2 (IC₅₀=48 nM), ARK5 (IC₅₀=64 nM). LY2606368 requires CDC25A and CDK2 to cause DNA damage.
Prexasertib dimesylate (33, 100 nM; for 7 hours) results in DNA damage during S-phase in HeLa cells.
Prexasertib dimesylate (8-250 nM; pre-treated for 15 minutes) inhibits CHK1 autophosphorylation (S296) and CHK2 autophosphorylation (S516) in HT-29 cells.
Prexasertib dimesylate (4 nM; 24 hours) results in a large shift in cell-cycle populations from G1 and G2-M to S-phase with an accompanied induction of H2AX phosphorylation in U-2 OS cells.
Prexasertib dimesylate (33 nM; for 12 hours) causes chromosomal fragmentation in HeLa cells. Prexasertib dimesylate (100 nM; 0.5 to 9 hours) induces replication stress and depletes the pool of available RPA2 for binding to DNA.

In Vivo: Prexasertib dimesylate (LY2606368 dimesylate; 1-10 mg/kg; SC; twice daily for 3 days, rest 4 days; for three cycles; for 64 days) causes growth inhibition in tumor xenografts.
Prexasertib dimesylate (15 mg/kg; SC) causes CHK1 inhibition in the blood and the phosphorylation of both H2AX (S139) and RPA2 (S4/S8).

相关产品：Apoptosis Compound Library  |  Anti-Aging Compound Library  |  Kinase Inhibitor Library  |  Anti-Cancer Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Bioactive Compound Library Plus  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Paclitaxel  |  Y-27632 dihydrochloride  |  SP600125  |  Sorafenib  |  Angiotensin II human  |  Staurosporine  |  5-Fluorouracil  |  Trametinib  |  MK-2206 dihydrochloride  |  Bortezomib  |  Tamoxifen  |  Acetylcysteine  |  Pexidartinib  |  Gemcitabine  |  BAY 11-7082  |  Decitabine  |  2-Deoxy-D-glucose  |  Temozolomide  |  Verteporfin  |  Ruxolitinib  |  Etoposide  |  Docetaxel  |  Dasatinib  |  DAPT  |  Everolimus

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。